| Year |
Citation |
Score |
| 2021 |
Janiszewska M, Stein S, Metzger Filho O, Eng J, Kingston NL, Harper NW, Rye IH, Alečković M, Trinh A, Murphy KC, Marangoni E, Cristea S, Oakes B, Winer EP, Krop I, ... ... Michor F, et al. The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2-positive breast cancer. Jci Insight. PMID 33886505 DOI: 10.1172/jci.insight.147617 |
0.336 |
|
| 2020 |
Shen YJ, Mishima Y, Shi J, Sklavenitis-Pistofidis R, Redd RA, Moschetta M, Manier S, Roccaro AM, Sacco A, Tai YT, Mercier FE, Kawano Y, Su NK, Berrios B, Doench J, ... ... Michor F, et al. Progression signature underlies clonal evolution and dissemination of multiple myeloma. Blood. PMID 33150374 DOI: 10.1016/J.Clml.2019.09.028 |
0.377 |
|
| 2020 |
Irurzun-Arana I, McDonald TO, Troconiz IF, Michor F. Pharmacokinetic profiles determine optimal combination treatment schedules in computational models of drug resistance. Cancer Research. PMID 32561532 DOI: 10.1158/0008-5472.Can-20-0056 |
0.351 |
|
| 2020 |
Shu S, Wu HJ, Ge JY, Zeid R, Harris IS, Jovanović B, Murphy K, Wang B, Qiu X, Endress JE, Reyes J, Lim K, Font-Tello A, Syamala S, Xiao T, ... ... Michor F, et al. Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. Molecular Cell. PMID 32416067 DOI: 10.1016/J.Molcel.2020.04.027 |
0.372 |
|
| 2020 |
Ge JY, Shu S, Kwon M, Jovanović B, Murphy K, Gulvady A, Fassl A, Trinh A, Kuang Y, Heavey GA, Luoma A, Paweletz C, Thorner AR, Wucherpfennig KW, Qi J, ... ... Michor F, et al. Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. Nature Communications. 11: 2350. PMID 32393766 DOI: 10.1038/S41467-020-16170-3 |
0.377 |
|
| 2020 |
Starrett JH, Guernet AA, Cuomo ME, Poels KE, van Alderwerelt van Rosenburgh IK, Nagelberg A, Farnsworth D, Price KS, Khan H, Ashtekar KD, Gaefele M, Ayeni D, Stewart TF, Kuhlmann A, Kaech S, ... ... Michor F, et al. Drug sensitivity and allele-specificity of first-line osimertinib resistance EGFR mutations. Cancer Research. PMID 32193290 DOI: 10.1158/0008-5472.Can-19-3819 |
0.387 |
|
| 2020 |
Murata K, Jadhav U, Madha S, van Es J, Dean J, Cavazza A, Wucherpfennig K, Michor F, Clevers H, Shivdasani RA. Ascl2-Dependent Cell Dedifferentiation Drives Regeneration of Ablated Intestinal Stem Cells. Cell Stem Cell. PMID 32084390 DOI: 10.1016/J.Stem.2019.12.011 |
0.328 |
|
| 2020 |
Stein S, Nardone A, Liu W, Cohen G, Guarducci C, Brown M, Jeselsohn R, Michor F. Abstract B16: Mathematical modeling identifies optimum palbociclib dosing schedules for the treatment of estrogen receptor-positive (ER+) breast cancer patients Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-B16 |
0.388 |
|
| 2020 |
Starrett JH, Guernet A, Cuomo ME, Poels K, van Alderwerelt van Rosenburgh IK, Nagelberg A, Farnsworth D, Price K, Khan H, Ashtekar KD, Gaefele M, Ayeni D, Stewart TF, Kuhlmann A, Kaech SM, ... ... Michor F, et al. Drug Sensitivity and Allele‐specificity of First‐line Osimertinib Resistance
EGFR
Mutations The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.00612 |
0.312 |
|
| 2020 |
Starrett J, Guernet A, Cuomo M, Poels K, van Alderwerelt van Rosenburgh I, Nagelberg A, Farnsworth D, Price K, Khan H, Ashtekar K, Gaefele M, Ayeni D, Stewart T, Kuhlmann A, Kaech S, ... ... Michor F, et al. B32 Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations Journal of Thoracic Oncology. 15: S36. DOI: 10.1016/J.Jtho.2019.12.097 |
0.311 |
|
| 2019 |
Shank K, Dunbar A, Koppikar P, Kleppe M, Teruya-Feldstein J, Csete I, Bhagwat N, Keller M, Kilpivaara O, Michor F, Levine RL, de Vargas Roditi L. Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms. Haematologica. PMID 31413098 DOI: 10.3324/Haematol.2018.203729 |
0.341 |
|
| 2019 |
Janiszewska M, Tabassum DP, Castaño Z, Cristea S, Yamamoto KN, Kingston NL, Murphy KC, Shu S, Harper NW, Del Alcazar CG, Alečković M, Ekram MB, Cohen O, Kwak M, Qin Y, ... ... Michor F, et al. Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments. Nature Cell Biology. 21: 879-888. PMID 31263265 DOI: 10.1038/S41556-019-0346-X |
0.34 |
|
| 2019 |
Yamamoto KN, Nakamura A, Liu LL, Stein S, Tramontano AC, Kartoun U, Shimizu T, Inoue Y, Asakuma M, Haeno H, Kong CY, Uchiyama K, Gonen M, Hur C, Michor F. Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. Plos One. 14: e0215409. PMID 31026288 DOI: 10.1371/Journal.Pone.0215409 |
0.337 |
|
| 2019 |
Yamamoto KN, Liu LL, Nakamura A, Haeno H, Michor F. Stochastic Evolution of Pancreatic Cancer Metastases During Logistic Clonal Expansion. Jco Clinical Cancer Informatics. 1-11. PMID 30901235 DOI: 10.1200/CCI.18.00079 |
0.309 |
|
| 2019 |
Ferlic J, Shi J, McDonald TO, Michor F. DIFFpop: A stochastic computational approach to simulate differentiation hierarchies with single cell barcoding. Bioinformatics (Oxford, England). PMID 30816920 DOI: 10.1093/Bioinformatics/Btz074 |
0.318 |
|
| 2019 |
Szulzewsky F, Hoellerbauer P, Wu H, Cimino PJ, Michor F, Paddison P, Vasioukhin V, Holland E. GENE-04. THE ONCOGENIC FUNCTIONS OF YAP1-GENE FUSIONS CAN BE INHIBITED BY DISRUPTION OF YAP1-TEAD INTERACTION Neuro-Oncology. 21: vi98-vi98. DOI: 10.1093/Neuonc/Noz175.406 |
0.373 |
|
| 2018 |
Chakrabarti S, Paek AL, Reyes J, Lasick KA, Lahav G, Michor F. Hidden heterogeneity and circadian-controlled cell fate inferred from single cell lineages. Nature Communications. 9: 5372. PMID 30560953 DOI: 10.1038/S41467-018-07788-5 |
0.367 |
|
| 2018 |
Hinohara K, Wu HJ, Vigneau S, McDonald TO, Igarashi KJ, Yamamoto KN, Madsen T, Fassl A, Egri SB, Papanastasiou M, Ding L, Peluffo G, Cohen O, Kales SC, Lal-Nag M, ... ... Michor F, et al. KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer Cell. PMID 30472020 DOI: 10.1016/J.Ccell.2018.10.014 |
0.365 |
|
| 2018 |
McDonald TO, Chakrabarti S, Michor F. Currently available bulk sequencing data do not necessarily support a model of neutral tumor evolution. Nature Genetics. PMID 30374067 DOI: 10.1038/S41588-018-0217-6 |
0.301 |
|
| 2018 |
Karaayvaz M, Cristea S, Gillespie SM, Patel AP, Mylvaganam R, Luo CC, Specht MC, Bernstein BE, Michor F, Ellisen LW. Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq. Nature Communications. 9: 3588. PMID 30181541 DOI: 10.1038/S41467-018-06052-0 |
0.403 |
|
| 2018 |
Jun HJ, Appleman VA, Wu HJ, Rose CM, Pineda JJ, Yeo AT, Delcuze B, Lee C, Gyuris A, Zhu H, Woolfenden S, Bronisz A, Nakano I, Chiocca EA, Bronson RT, ... ... Michor F, et al. A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine. Nature Communications. 9: 3116. PMID 30082792 DOI: 10.1038/S41467-018-05036-4 |
0.338 |
|
| 2018 |
Cimino PJ, Kim Y, Wu HJ, Alexander J, Wirsching HG, Szulzewsky F, Pitter K, Ozawa T, Wang J, Vazquez J, Arora S, Rabadan R, Levine R, Michor F, Holland EC. Increased expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma. Genes & Development. PMID 29632085 DOI: 10.1101/Gad.312157.118 |
0.301 |
|
| 2018 |
Stein S, Zhao R, Haeno H, Vivanco I, Michor F. Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. Plos Computational Biology. 14: e1005924. PMID 29293494 DOI: 10.1371/Journal.Pcbi.1005924 |
0.403 |
|
| 2018 |
Shen Y, Mishima Y, Shi J, Moschetta M, Manier S, Roccaro AM, Mercier F, Takagi S, Kawano Y, Tsukamoto S, Sahin I, Sacco A, Huynh D, Berrios B, Pistofidis R, ... ... Michor F, et al. Deciphering Clonal Evolution and Dissemination of Multiple Myeloma Cells In Vivo Blood. 132: 55-55. DOI: 10.1182/Blood-2018-99-113916 |
0.419 |
|
| 2018 |
Alcazar CRGd, Huh S, Ekram MB, Trinh A, Liu LL, Beca F, Xiaoyuan Z, Kwak M, Bergholtz H, Su Y, Ding L, Russnes HG, Richardson AL, Babski K, Kim EMH, ... ... Michor F, et al. Abstract A15: Immune-related changes in breast cancer tumor evolution Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-A15 |
0.411 |
|
| 2018 |
Janiszewska M, Tabassum DP, Marusyk A, Ekram MB, Castaño Z, Kingston NL, Qin Y, Laszewski T, Kwak M, Nakamura K, Fan R, Michor F, McAllister SS, Polyak K. Abstract PR02: Minor clones can drive polyclonal metastasis by affecting immune microenvironment Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-Pr02 |
0.416 |
|
| 2018 |
Alcazar CRGd, Huh S, Ekram MB, Trinh A, Liu LL, Beca F, Xiaoyuan Z, Kwak M, Bergholtz H, Su Y, Ding L, Russnes HG, Richardson AL, Babski K, Kim EMH, ... ... Michor F, et al. Abstract A21: Characterization of the immune environment in the in situ to invasive breast carcinoma transition Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-A21 |
0.397 |
|
| 2018 |
Mercier F, Shi J, Sykes D, Oki T, Miller E, Vasic R, Zhu A, Severe N, Schajnovitz A, Man C, Kfoury Y, Lee D, Doench J, Hide W, Michor F, et al. In Vivo Profiling of Leukemic Stem Cell Fitness Identifies Therapeutically Actionable Determinants of Growth Experimental Hematology. 64: S86. DOI: 10.1016/J.Exphem.2018.06.095 |
0.317 |
|
| 2017 |
Riester M, Xu Q, Moreira A, Zheng J, Michor F, Downey RJ. The Warburg effect: persistence of stem cell metabolism in cancers as a failure of differentiation. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29045536 DOI: 10.1093/Annonc/Mdx645 |
0.326 |
|
| 2017 |
Smith KS, Liu LL, Ganesan S, Michor F, De S. Nuclear topology modulates the mutational landscapes of cancer genomes. Nature Structural & Molecular Biology. PMID 28967881 DOI: 10.1038/Nsmb.3474 |
0.364 |
|
| 2017 |
Malone CF, Emerson C, Ingraham R, Barbosa W, Guerra S, Yoon H, Liu LL, Michor F, Haigis M, Macleod KF, Maertens O, Cichowski K. mTOR and HDAC inhibitors converge on the TXNIP/thioredoxin pathway to cause catastrophic oxidative stress and regression of RAS-driven tumors. Cancer Discovery. PMID 28963352 DOI: 10.1158/2159-8290.Cd-17-0177 |
0.394 |
|
| 2017 |
Smith ZD, Shi J, Gu H, Donaghey J, Clement K, Cacchiarelli D, Gnirke A, Michor F, Meissner A. Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer. Nature. 549: 543-547. PMID 28959968 DOI: 10.1038/Nature23891 |
0.317 |
|
| 2017 |
Maruvka YE, Mouw KW, Karlic R, Parasuraman P, Kamburov A, Polak P, Haradhvala NJ, Hess JM, Rheinbay E, Brody Y, Koren A, Braunstein LZ, D'Andrea A, Lawrence MS, Bass A, ... ... Michor F, et al. Analysis of somatic microsatellite indels identifies driver events in human tumors. Nature Biotechnology. PMID 28892075 DOI: 10.1038/Nbt.3966 |
0.377 |
|
| 2017 |
Zhao R, Catalano P, DeGruttola VG, Michor F. Estimating mono- and bi-phasic regression parameters using a mixture piecewise linear Bayesian hierarchical model. Plos One. 12: e0180756. PMID 28723910 DOI: 10.1371/Journal.Pone.0180756 |
0.318 |
|
| 2017 |
Gil Del Alcazar CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F, Zi X, Kwak M, Bergholtz H, Su Y, Ding L, Russnes HG, Richardson AL, Babski K, Min Hui Kim E, ... ... Michor F, et al. Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. Cancer Discovery. PMID 28652380 DOI: 10.1158/2159-8290.Cd-17-0222 |
0.341 |
|
| 2017 |
Chakrabarti S, Michor F. Pharmacokinetics and drug-interactions determine optimum combination strategies in computational models of cancer evolution. Cancer Research. PMID 28566331 DOI: 10.1158/0008-5472.Can-16-2871 |
0.376 |
|
| 2017 |
Temko DP, Cheng YK, Polyak K, Michor F. Mathematical modeling links pregnancy-associated changes and breast cancer risk. Cancer Research. PMID 28360138 DOI: 10.1158/0008-5472.Can-16-2504 |
0.39 |
|
| 2017 |
McDonald TO, Michor F. SIApopr: A computational method to simulate evolutionary branching trees for analysis of tumor clonal evolution. Bioinformatics (Oxford, England). PMID 28334409 DOI: 10.1093/Bioinformatics/Btx146 |
0.306 |
|
| 2017 |
Riester M, Wu HJ, Zehir A, Gönen M, Moreira AL, Downey RJ, Michor F. Distance in cancer gene expression from stem cells predicts patient survival. Plos One. 12: e0173589. PMID 28333954 DOI: 10.1371/Journal.Pone.0173589 |
0.439 |
|
| 2017 |
Han L, Wu HJ, Zhu H, Kim KY, Marjani SL, Riester M, Euskirchen G, Zi X, Yang J, Han J, Snyder M, Park IH, Irizarry R, Weissman SM, Michor F, et al. Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells. Nucleic Acids Research. PMID 28126923 DOI: 10.1093/Nar/Gkx026 |
0.336 |
|
| 2017 |
Gibson CJ, Lindsley RC, Tchekmedyian V, Mar BG, Shi J, Jaiswal S, Bosworth A, Francisco L, He J, Bansal A, Morgan EA, Lacasce AS, Freedman AS, Fisher DC, Jacobsen E, ... ... Michor F, et al. Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016716712. PMID 28068180 DOI: 10.1200/Jco.2016.71.6712 |
0.312 |
|
| 2017 |
Mercier F, Shi J, Sykes DB, Miller E, Oki T, Man C, Yan X, Kfoury Y, Lee D, Doench JG, Michor F, Scadden DT. A Genome-Wide, In Vivo, Dropout CRISPR Screen in Acute Myeloid Leukemia Identifies an Essential Role for Beta-Galactosylation in Leukemic Cell Homing Blood. 130: 2493-2493. DOI: 10.1182/Blood.V130.Suppl_1.2493.2493 |
0.407 |
|
| 2017 |
Maruvka YE, Mouw KW, Karlic R, Parasuraman R, Kamburov A, Polak P, Haradhvala NJ, Hess JM, Rheinbay E, Brody Y, Braunstein LZ, D’Andrea A, Lawrence MS, Bass A, Bernards A, ... Michor F, et al. Abstract LB-280: The landscape of somatic microsatellite indels across cancer: detection and identification of driver events Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-280 |
0.372 |
|
| 2017 |
Downey R, Riester M, Wu H, Zheng J, Michor F. P1.03-003 The Warburg Effect: Persistence of Stem Cell Metabolism in Lung Cancer as Failure of Differentiation Journal of Thoracic Oncology. 12: S543-S544. DOI: 10.1016/J.Jtho.2016.11.674 |
0.32 |
|
| 2017 |
Downey R, Riester M, Wu H, Moreira A, Michor F. P3.01-059 A Stem-Cell Oriented Phylogeny of Non-Small Cell Lung Cancers Journal of Thoracic Oncology. 12: S1155-S1156. DOI: 10.1016/J.Jtho.2016.11.1625 |
0.351 |
|
| 2017 |
Downey R, Seeley E, Moreira A, Wu H, Lee C, Adusumilli P, Kilby G, Michor F. P2.01-026 A Mass Spectrometry Based Stem Cell-Oriented Phylogeny of Intra-Tumoral NSCLC Subclones Journal of Thoracic Oncology. 12: S800. DOI: 10.1016/J.Jtho.2016.11.1078 |
0.33 |
|
| 2016 |
Yu HA, Sima C, Feldman D, Liu LL, Vaitheesvaran B, Cross J, Rudin CM, Kris MG, Pao W, Michor F, Riely GJ. Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28073786 DOI: 10.1093/Annonc/Mdw556 |
0.306 |
|
| 2016 |
Liu LL, Brumbaugh J, Bar-Nur O, Smith Z, Stadtfeld M, Meissner A, Hochedlinger K, Michor F. Probabilistic Modeling of Reprogramming to Induced Pluripotent Stem Cells. Cell Reports. 17: 3395-3406. PMID 28009305 DOI: 10.1016/J.Celrep.2016.11.080 |
0.35 |
|
| 2016 |
Gao R, Davis A, McDonald TO, Sei E, Shi X, Wang Y, Tsai PC, Casasent A, Waters J, Zhang H, Meric-Bernstam F, Michor F, Navin NE. Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nature Genetics. PMID 27526321 DOI: 10.1038/Ng.3641 |
0.42 |
|
| 2016 |
Wee B, Pietras A, Ozawa T, Bazzoli E, Podlaha O, Antczak C, Westermark B, Nelander S, Uhrbom L, Forsberg-Nilsson K, Djaballah H, Michor F, Holland EC. ABCG2 regulates self-renewal and stem cell marker expression but not tumorigenicity or radiation resistance of glioma cells. Scientific Reports. 6: 25956. PMID 27456282 DOI: 10.1038/Srep25956 |
0.365 |
|
| 2016 |
Altrock PM, Brendel C, Renella R, Orkin SH, Williams DA, Michor F. Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease. American Journal of Hematology. 91: 931-7. PMID 27299299 DOI: 10.1002/Ajh.24449 |
0.364 |
|
| 2016 |
Tang M, Zhao R, van de Velde H, Tross JG, Mitsiades CS, Viselli S, Neuwirth R, Esseltine DL, Anderson KC, Ghobrial IM, San Miguel J, Richardson PG, Tomasson MH, Michor F. Myeloma cell dynamics in response to treatment supports a model of hierarchical differentiation and clonal evolution. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27006493 DOI: 10.1158/1078-0432.Ccr-15-2793 |
0.366 |
|
| 2016 |
Gibson CJ, Lindsley RC, Tchekmedyian V, Shi J, Mar BG, Jaiswal S, Bosworth A, Francisco LF, He J, Morgan EA, LaCasce AS, Koreth J, Ho VT, Ritz J, Nikiforow S, ... ... Michor F, et al. Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma Blood. 128: 986-986. DOI: 10.1182/Blood.V128.22.986.986 |
0.359 |
|
| 2016 |
Mishima Y, Shi J, Moschetta M, Shen Y, Manier S, Roccaro AM, Mercier F, Takagi S, Kawano Y, Tsukamoto S, Sahin I, Sacco A, Hatake K, Michor F, Scadden DT, et al. In Vivo Analysis of Clonal Evolution of Multiple Myeloma Blood. 128: 799-799. DOI: 10.1182/Blood.V128.22.799.799 |
0.394 |
|
| 2016 |
Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Weigelt B, Sakr RA, King TA, Chandarlapaty S, Reis-Filho JS, Hanker AB, Arteaga CL, Yeon PS, Michor F, Polyak K. Abstract PR05: The effect of chemotherapy on HER2+ breast cancer heterogeneity measured by STAR-FISH: Detection of PIK3CA mutation and HER2 amplification at single-cell level in situ Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-Pr05 |
0.45 |
|
| 2016 |
Altrock PM, Brendel C, Renella R, Orkin SH, Williams DA, Michor F. 314. Mathematical Modeling of Erythrocyte Chimerism Informs Clinical Strategies for Sickle Cell Disease Molecular Therapy. 24: S126-S127. DOI: 10.1016/S1525-0016(16)33123-9 |
0.364 |
|
| 2015 |
Altrock PM, Liu LL, Michor F. The mathematics of cancer: integrating quantitative models. Nature Reviews. Cancer. 15: 730-45. PMID 26597528 DOI: 10.1038/Nrc4029 |
0.371 |
|
| 2015 |
Michor F, Beal K. Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort. Cell. 163: 1059-1063. PMID 26590416 DOI: 10.1016/J.Cell.2015.11.002 |
0.364 |
|
| 2015 |
Liu LL, Li F, Pao W, Michor F. Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients. Plos One. 10: e0141665. PMID 26536620 DOI: 10.1371/Journal.Pone.0141665 |
0.407 |
|
| 2015 |
Foo J, Liu LL, Leder K, Riester M, Iwasa Y, Lengauer C, Michor F. An Evolutionary Approach for Identifying Driver Mutations in Colorectal Cancer. Plos Computational Biology. 11: e1004350. PMID 26379039 DOI: 10.1371/Journal.Pcbi.1004350 |
0.448 |
|
| 2015 |
Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, Weigelt B, Hanker AB, Chandarlapaty S, King TA, Reis-Filho JS, Arteaga CL, Park SY, Michor F, Polyak K. In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nature Genetics. 47: 1212-9. PMID 26301495 DOI: 10.1038/Ng.3391 |
0.387 |
|
| 2015 |
Mumenthaler SM, Foo J, Choi NC, Heise N, Leder K, Agus DB, Pao W, Michor F, Mallick P. The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Informatics. 14: 19-31. PMID 26244007 DOI: 10.4137/Cin.S19338 |
0.425 |
|
| 2015 |
Roccaro AM, Mishima Y, Sacco A, Moschetta M, Tai YT, Shi J, Zhang Y, Reagan MR, Huynh D, Kawano Y, Sahin I, Chiarini M, Manier S, Cea M, Aljawai Y, ... ... Michor F, et al. CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Reports. 12: 622-35. PMID 26190113 DOI: 10.1016/J.Celrep.2015.06.059 |
0.353 |
|
| 2015 |
Bhang HE, Ruddy DA, Krishnamurthy Radhakrishna V, Caushi JX, Zhao R, Hims MM, Singh AP, Kao I, Rakiec D, Shaw P, Balak M, Raza A, Ackley E, Keen N, Schlabach MR, ... ... Michor F, et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nature Medicine. 21: 440-8. PMID 25849130 DOI: 10.1038/Nm.3841 |
0.377 |
|
| 2015 |
Selmecki AM, Maruvka YE, Richmond PA, Guillet M, Shoresh N, Sorenson AL, De S, Kishony R, Michor F, Dowell R, Pellman D. Polyploidy can drive rapid adaptation in yeast. Nature. 519: 349-52. PMID 25731168 DOI: 10.1038/Nature14187 |
0.381 |
|
| 2015 |
Ashcroft P, Michor F, Galla T. Stochastic tunneling and metastable states during the somatic evolution of cancer. Genetics. 199: 1213-28. PMID 25624316 DOI: 10.1534/Genetics.114.171553 |
0.383 |
|
| 2015 |
Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, Hricik T, Bhagwat N, McKenney AS, Papalexi E, Abdel-Wahab O, Rampal R, Marubayashi S, Chen JJ, Romanet V, ... ... Michor F, et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discovery. 5: 316-31. PMID 25572172 DOI: 10.1158/2159-8290.Cd-14-0736 |
0.346 |
|
| 2015 |
Michor F. Mathematical Models of Cancer Evolution and Cure Blood. 126: SCI-54-SCI-54. DOI: 10.1182/Blood.V126.23.Sci-54.Sci-54 |
0.406 |
|
| 2015 |
Mishima Y, Paiva B, Shi J, Massoud M, Manier S, Flores L, Perilla-Glen A, Aljawai Y, Huynh D, Takagi S, Roccaro AM, Sacco A, Alignani D, Mateos MV, Bladé J, ... ... Michor F, et al. Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma Blood. 126: 23-23. DOI: 10.1182/Blood.V126.23.23.23 |
0.369 |
|
| 2015 |
Bainer R, Yui Y, Mumenthaler S, Mallick P, Liu L, Wu H, Podlaha O, Michor F, Liphardt J, Licht J, Weaver V. Abstract PR09: Extracellular stiffness cues drive spatial reorganization of the genome to globally constrain RNA abundance Cancer Research. 75. DOI: 10.1158/1538-7445.Compsysbio-Pr09 |
0.31 |
|
| 2015 |
Mumenthaler S, Foo J, Choi N, Pao W, Agus D, Michor F, Mallick P. Abstract PR16: Spatio-temporal heterogeneity in the tumor microenvironment influences the evolutionary dynamics of drug resistance Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-Pr16 |
0.414 |
|
| 2015 |
Michor F. Abstract IA05: Evolution of glioblastoma subtypes Brain. 75. DOI: 10.1158/1538-7445.Brain15-Ia05 |
0.384 |
|
| 2015 |
Bhang HC, Ruddy DA, Radhakrishna VK, Zhao R, Kao I, Rakiec D, Shaw P, Balak M, Caushi JX, Ackley E, Keen N, Schlabach MR, Palmer M, Sellers WR, Michor F, et al. Abstract 2847: High complexity barcoding to study clonal dynamics in response to cancer therapy Cancer Research. 75: 2847-2847. DOI: 10.1158/1538-7445.Am2015-2847 |
0.41 |
|
| 2015 |
Mishima Y, Paiva B, Shi J, Massoud M, Manier S, Perilla-Glen A, Aljawai Y, Takagi S, Huynh D, Roccaro A, Sacco A, Alignani D, Mateos M, Blade J, Lahuerta J, ... ... Michor F, et al. Abstract A82: Prognostic relevance and genomic profile of circulating tumor cells in multiple myeloma Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A82 |
0.4 |
|
| 2015 |
Lee C, Wu H, Moreira AL, Seeley EH, Walsh C, Downey RJ, Michor F. Abstract A21: Proteomic profiling to elucidate intratumoral heterogeneity and cancer evolution in lung cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A21 |
0.437 |
|
| 2014 |
Shaknovich R, De S, Michor F. Epigenetic diversity in hematopoietic neoplasms. Biochimica Et Biophysica Acta. 1846: 477-84. PMID 25240947 DOI: 10.1016/J.Bbcan.2014.09.003 |
0.388 |
|
| 2014 |
Olshen A, Tang M, Cortes J, Gonen M, Hughes T, Branford S, Quintás-Cardama A, Michor F. Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. Haematologica. 99: 1701-9. PMID 25216683 DOI: 10.3324/Haematol.2013.085977 |
0.335 |
|
| 2014 |
Ozawa T, Riester M, Cheng YK, Huse JT, Squatrito M, Helmy K, Charles N, Michor F, Holland EC. Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. Cancer Cell. 26: 288-300. PMID 25117714 DOI: 10.1016/J.Ccr.2014.06.005 |
0.338 |
|
| 2014 |
Marusyk A, Tabassum DP, Altrock PM, Almendro V, Michor F, Polyak K. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature. 514: 54-8. PMID 25079331 DOI: 10.1038/Nature13556 |
0.354 |
|
| 2014 |
Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, Chen K, Scheet P, Vattathil S, Liang H, Multani A, Zhang H, Zhao R, Michor F, Meric-Bernstam F, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 512: 155-60. PMID 25079324 DOI: 10.1038/Nature13600 |
0.387 |
|
| 2014 |
Maruvka YE, Tang M, Michor F. On the validity of using increases in 5-year survival rates to measure success in the fight against cancer. Plos One. 9: e83100. PMID 25054541 DOI: 10.1371/Journal.Pone.0083100 |
0.334 |
|
| 2014 |
Podlaha O, De S, Gonen M, Michor F. Histone modifications are associated with transcript isoform diversity in normal and cancer cells. Plos Computational Biology. 10: e1003611. PMID 24901363 DOI: 10.1371/Journal.Pcbi.1003611 |
0.305 |
|
| 2014 |
Guancial EA, Werner L, Bellmunt J, Bamias A, Choueiri TK, Ross R, Schutz FA, Park RS, O'Brien RJ, Hirsch MS, Barletta JA, Berman DM, Lis R, Loda M, Stack EC, ... ... Michor F, et al. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Medicine. 3: 835-44. PMID 24846059 DOI: 10.1002/Cam4.262 |
0.381 |
|
| 2014 |
Riester M, Wei W, Waldron L, Culhane AC, Trippa L, Oliva E, Kim SH, Michor F, Huttenhower C, Parmigiani G, Birrer MJ. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. Journal of the National Cancer Institute. 106. PMID 24700803 DOI: 10.1093/Jnci/Dju048 |
0.32 |
|
| 2014 |
Michor F, Weaver VM. Understanding tissue context influences on intratumour heterogeneity. Nature Cell Biology. 16: 301-2. PMID 24691256 DOI: 10.1038/Ncb2942 |
0.346 |
|
| 2014 |
Foo J, Michor F. Evolution of acquired resistance to anti-cancer therapy. Journal of Theoretical Biology. 355: 10-20. PMID 24681298 DOI: 10.1016/J.Jtbi.2014.02.025 |
0.38 |
|
| 2014 |
Leder K, Pitter K, Laplant Q, Hambardzumyan D, Ross BD, Chan TA, Holland EC, Michor F. Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. Cell. 156: 603-16. PMID 24485463 DOI: 10.1016/J.Cell.2013.12.029 |
0.346 |
|
| 2014 |
Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, Gonzalez-Farre X, Muñoz M, Russnes HG, Helland A, Rye IH, Borresen-Dale AL, Maruyama R, van Oudenaarden A, Dowsett M, ... ... Michor F, et al. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Reports. 6: 514-27. PMID 24462293 DOI: 10.1016/J.Celrep.2013.12.041 |
0.399 |
|
| 2014 |
Almendro V, Kim HJ, Cheng YK, Gönen M, Itzkovitz S, Argani P, van Oudenaarden A, Sukumar S, Michor F, Polyak K. Genetic and phenotypic diversity in breast tumor metastases. Cancer Research. 74: 1338-48. PMID 24448237 DOI: 10.1158/0008-5472.Can-13-2357-T |
0.426 |
|
| 2014 |
Birrer MJ, Riester M, Wei W, Waldron L, Culhane A, Trippa L, Oliva E, Kim S, Michor F, Huttenhower C, Parmigiani G. Meta-analysis of public microarray databases for prognostic and predictive gene signatures of late-stage ovarian cancer. Journal of Clinical Oncology. 32: 5531-5531. DOI: 10.1200/Jco.2014.32.15_Suppl.5531 |
0.331 |
|
| 2014 |
Shank KR, Koppikar P, Bhagwat N, Keller MD, Michor F, Levine RL, De Vargas Roditi L. Mathematical Optimization of JAK Inhibitor Dose and Scheduling for MPN Patients Blood. 124: 911-911. DOI: 10.1182/Blood.V124.21.911.911 |
0.337 |
|
| 2014 |
Mercier F, Shi J, Sykes D, Kfoury YS, Yusuf RZ, Miller E, Vasic R, Zhu A, Michor F, Hide W, Scadden DT. Identification of a Gene Expression Signature Characterizing Clonal Fitness and Dominance in Vivo in a Murine Model of MLL-AF9 Leukemia Blood. 124: 2383-2383. DOI: 10.1182/Blood.V124.21.2383.2383 |
0.388 |
|
| 2014 |
Wang Y, Navin N, Waters J, Leung M, Unruh A, Shi X, Roh W, Chen K, Scheet P, Vattathil S, Liang H, Multani A, Zhang H, Meric-Bernstam F, Michor F, et al. Abstract LB-310: Single cell genome sequencing reveals clonal stability and diversity in breast cancer Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-310 |
0.454 |
|
| 2014 |
Riester M, Wei W, Culhane AC, Trippa L, Michor F, Huttenhower C, Parmigiani G, Birrer M. Abstract 2355: Risk prediction for late-stage ovarian cancer by meta-analysis of 1,525 patient samples Cancer Research. 74: 2355-2355. DOI: 10.1158/1538-7445.Am2014-2355 |
0.342 |
|
| 2014 |
Bainer R, Yui Y, Mumenthaler S, Mallick P, Podlaha O, Michor F, Liphardt J, Licht J, Weaver V. Abstract 2344: 3D extracellular stiffness cues drive localized changes in gene expression Cancer Research. 74: 2344-2344. DOI: 10.1158/1538-7445.Am2014-2344 |
0.364 |
|
| 2013 |
Haeno H, Maruvka YE, Iwasa Y, Michor F. Stochastic Tunneling of Two Mutations in a Population of Cancer Cells. Plos One. 8: e65724. PMID 23840359 DOI: 10.1371/Journal.Pone.0065724 |
0.438 |
|
| 2013 |
Zhao R, Michor F. Patterns of proliferative activity in the colonic crypt determine crypt stability and rates of somatic evolution. Plos Computational Biology. 9: e1003082. PMID 23785264 DOI: 10.1371/Journal.Pcbi.1003082 |
0.405 |
|
| 2013 |
Choudhury S, Almendro V, Merino VF, Wu Z, Maruyama R, Su Y, Martins FC, Fackler MJ, Bessarabova M, Kowalczyk A, Conway T, Beresford-Smith B, Macintyre G, Cheng YK, Lopez-Bujanda Z, ... ... Michor F, et al. Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics. Cell Stem Cell. 13: 117-30. PMID 23770079 DOI: 10.1016/J.Stem.2013.05.004 |
0.39 |
|
| 2013 |
Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, Michor F, Zhao Z, Pao W. Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Research. 23: 1434-45. PMID 23733853 DOI: 10.1101/Gr.152322.112 |
0.388 |
|
| 2013 |
Agus DB, Alexander JF, Arap W, Ashili S, Aslan JE, Austin RH, Backman V, Bethel KJ, Bonneau R, Chen WC, Chen-Tanyolac C, Choi NC, Curley SA, Dallas M, ... ... Michor F, et al. A physical sciences network characterization of non-tumorigenic and metastatic cells. Scientific Reports. 3: 1449. PMID 23618955 DOI: 10.1038/Srep01449 |
0.369 |
|
| 2013 |
Liu L, De S, Michor F. DNA replication timing and higher-order nuclear organization determine single-nucleotide substitution patterns in cancer genomes. Nature Communications. 4: 1502. PMID 23422670 DOI: 10.1038/Ncomms2502 |
0.328 |
|
| 2013 |
De S, Shaknovich R, Riester M, Elemento O, Geng H, Kormaksson M, Jiang Y, Woolcock B, Johnson N, Polo JM, Cerchietti L, Gascoyne RD, Melnick A, Michor F. Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. Plos Genetics. 9: e1003137. PMID 23326238 DOI: 10.1371/Journal.Pgen.1003137 |
0.337 |
|
| 2013 |
Garrett-Bakelman FE, Li S, Hricik T, Chung SS, Bar H, Brown AL, Patel JP, Rapoport F, Liu L, Sheridan C, Ishii J, Zumbo P, Gandara J, Lewis ID, To LB, ... ... Michor F, et al. Epigenetic Deregulation In Relapsed Acute Myeloid Leukemia Blood. 122: 2499-2499. DOI: 10.1182/Blood.V122.21.2499.2499 |
0.344 |
|
| 2013 |
Almendro V, Cheng Y, Gönen M, Itzkovitz S, Marusyk A, Ametller E, Gonzalez-Farre X, Muñoz M, Russnes H, Helland Å, Rye I, Borresen-Dale AL, Maruyama R, Oudenaarden Av, Dowsett M, ... ... Michor F, et al. Abstract C47: Inference of tumor evolution during chemotherapy by computational modeling and single cell analysis of diversity. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C47 |
0.443 |
|
| 2012 |
Foo J, Chmielecki J, Pao W, Michor F. Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 1583-93. PMID 22982659 DOI: 10.1097/Jto.0B013E31826146Ee |
0.353 |
|
| 2012 |
Martins FC, De S, Almendro V, Gönen M, Park SY, Blum JL, Herlihy W, Ethington G, Schnitt SJ, Tung N, Garber JE, Fetten K, Michor F, Polyak K. Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discovery. 2: 503-11. PMID 22628410 DOI: 10.1158/2159-8290.Cd-11-0325 |
0.397 |
|
| 2012 |
Iwami S, Haeno H, Michor F. A race between tumor immunoescape and genome maintenance selects for optimum levels of (epi)genetic instability. Plos Computational Biology. 8: e1002370. PMID 22359489 DOI: 10.1371/Journal.Pcbi.1002370 |
0.3 |
|
| 2012 |
Podlaha O, Riester M, De S, Michor F. Evolution of the cancer genome. Trends in Genetics : Tig. 28: 155-63. PMID 22342180 DOI: 10.1016/J.Tig.2012.01.003 |
0.376 |
|
| 2012 |
Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 148: 362-75. PMID 22265421 DOI: 10.1016/J.Cell.2011.11.060 |
0.402 |
|
| 2012 |
Riester M, Werner L, Molins JB, Selvarajah S, Weir B, Stack EC, Park RS, O'Brien R, Schutz FAB, Choueiri TK, Signoretti S, Gallardo E, Rojo F, Lloreta Trull J, Marchionni L, ... ... Michor F, et al. External validation of somatic copy number alteration (SCNA) at chromosome 1q23.3 in advanced urothelial carcinoma (UC). Journal of Clinical Oncology. 30: 4585-4585. DOI: 10.1200/Jco.2012.30.15_Suppl.4585 |
0.343 |
|
| 2012 |
Rosenberg JE, Werner L, Bamias A, Choueiri TK, Schutz FAB, Park RS, O'Brien R, Guancial EA, Ross RW, Berman DM, Riester M, Lis R, Loda MF, Stack EC, Michor F, et al. FGFR3 protein expression and gene mutation in primary and metastatic urothelial carcinoma (UC) tumors. Journal of Clinical Oncology. 30: 4577-4577. DOI: 10.1200/Jco.2012.30.15_Suppl.4577 |
0.361 |
|
| 2012 |
Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Abstract 3961: Computational modeling of pancreatic cancer reveals growth and dissemination kinetics and suggests optimum treatment strategies Cancer Research. 72: 3961-3961. DOI: 10.1158/1538-7445.Am2012-3961 |
0.399 |
|
| 2012 |
Agus DB, Michor F. The sciences converge to fight cancer Nature Physics. 8: 773-774. DOI: 10.1038/Nphys2464 |
0.33 |
|
| 2011 |
Leder K, Foo J, Skaggs B, Gorre M, Sawyers CL, Michor F. Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. Plos One. 6: e27682. PMID 22140458 DOI: 10.1371/Journal.Pone.0027682 |
0.374 |
|
| 2011 |
De S, Michor F. DNA replication timing and long-range DNA interactions predict mutational landscapes of cancer genomes. Nature Biotechnology. 29: 1103-8. PMID 22101487 DOI: 10.1038/Nbt.2030 |
0.362 |
|
| 2011 |
Mumenthaler SM, Foo J, Leder K, Choi NC, Agus DB, Pao W, Mallick P, Michor F. Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Molecular Pharmaceutics. 8: 2069-79. PMID 21995722 DOI: 10.1021/Mp200270V |
0.428 |
|
| 2011 |
Hambardzumyan D, Cheng YK, Haeno H, Holland EC, Michor F. The probable cell of origin of NF1- and PDGF-driven glioblastomas. Plos One. 6: e24454. PMID 21931722 DOI: 10.1371/Journal.Pone.0024454 |
0.412 |
|
| 2011 |
Michor F, Liphardt J, Ferrari M, Widom J. What does physics have to do with cancer? Nature Reviews. Cancer. 11: 657-70. PMID 21850037 DOI: 10.1038/Nrc3092 |
0.374 |
|
| 2011 |
Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, Wang L, Amato KR, Arcila M, Sos ML, Socci ND, Viale A, de Stanchina E, Ginsberg MS, Thomas RK, ... ... Michor F, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Science Translational Medicine. 3: 90ra59. PMID 21734175 DOI: 10.1126/Scitranslmed.3002356 |
0.399 |
|
| 2011 |
De S, Michor F. DNA secondary structures and epigenetic determinants of cancer genome evolution. Nature Structural & Molecular Biology. 18: 950-5. PMID 21725294 DOI: 10.1038/Nsmb.2089 |
0.354 |
|
| 2011 |
Tang M, Gonen M, Quintas-Cardama A, Cortes J, Kantarjian H, Field C, Hughes TP, Branford S, Michor F. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood. 118: 1622-31. PMID 21653938 DOI: 10.1182/Blood-2011-02-339267 |
0.34 |
|
| 2011 |
Klinakis A, Lobry C, Abdel-Wahab O, Oh P, Haeno H, Buonamici S, van De Walle I, Cathelin S, Trimarchi T, Araldi E, Liu C, Ibrahim S, Beran M, Zavadil J, Efstratiadis A, ... ... Michor F, et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature. 473: 230-3. PMID 21562564 DOI: 10.1038/Nature09999 |
0.338 |
|
| 2011 |
Iwasa Y, Michor F. Evolutionary dynamics of intratumor heterogeneity. Plos One. 6: e17866. PMID 21479218 DOI: 10.1371/Journal.Pone.0017866 |
0.325 |
|
| 2011 |
Durrett R, Foo J, Leder K, Mayberry J, Michor F. Intratumor heterogeneity in evolutionary models of tumor progression. Genetics. 188: 461-77. PMID 21406679 DOI: 10.1534/Genetics.110.125724 |
0.409 |
|
| 2011 |
Foo J, Leder K, Michor F. Stochastic dynamics of cancer initiation. Physical Biology. 8: 015002. PMID 21301064 DOI: 10.1088/1478-3975/8/1/015002 |
0.463 |
|
| 2011 |
De Vargas Roditi L, Michor F. Evolutionary dynamics of BRCA1 alterations in breast tumorigenesis. Journal of Theoretical Biology. 273: 207-15. PMID 21194536 DOI: 10.1016/J.Jtbi.2010.12.033 |
0.411 |
|
| 2011 |
Cheng Y, Beroukhim R, Levine RL, Mellinghoff IK, Holland EC, Michor F. Abstract LB-26: A mathematical methodology for determining the temporal order of pathway alterations in cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-26 |
0.429 |
|
| 2011 |
Cheng YK, Beroukhim R, Levine RL, Mellinghoff IK, Michor F. Reply to Parsons: Many tumor types follow the monoclonal model of tumor initiation Proceedings of the National Academy of Sciences of the United States of America. 108: E16. DOI: 10.1073/Pnas.1018584108 |
0.422 |
|
| 2011 |
Taylor J, Reister M, Koppie T, Feifer A, Cordon-Cardo C, Downey R, Michor F, Bochner B. 1361 GENE EXPRESSION PROFILES IN PATIENTS WITH UROTHELIAL CANCER UNDERGOING RADICAL CYSTECTOMY Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1183 |
0.317 |
|
| 2010 |
Leder K, Holland EC, Michor F. The therapeutic implications of plasticity of the cancer stem cell phenotype. Plos One. 5: e14366. PMID 21179426 DOI: 10.1371/journal.pone.0014366 |
0.362 |
|
| 2010 |
Michor F, Polyak K. The origins and implications of intratumor heterogeneity. Cancer Prevention Research (Philadelphia, Pa.). 3: 1361-4. PMID 20959519 DOI: 10.1158/1940-6207.Capr-10-0234 |
0.39 |
|
| 2010 |
Attolini CS, Cheng YK, Beroukhim R, Getz G, Abdel-Wahab O, Levine RL, Mellinghoff IK, Michor F. A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proceedings of the National Academy of Sciences of the United States of America. 107: 17604-9. PMID 20864632 DOI: 10.1073/Pnas.1009117107 |
0.437 |
|
| 2010 |
Durrett R, Foo J, Leder K, Mayberry J, Michor F. Evolutionary dynamics of tumor progression with random fitness values. Theoretical Population Biology. 78: 54-66. PMID 20488197 DOI: 10.1016/J.Tpb.2010.05.001 |
0.444 |
|
| 2010 |
Riester M, Stephan-Otto Attolini C, Downey RJ, Singer S, Michor F. A differentiation-based phylogeny of cancer subtypes. Plos Computational Biology. 6: e1000777. PMID 20463876 DOI: 10.1371/Journal.Pcbi.1000777 |
0.401 |
|
| 2010 |
Park SY, Gönen M, Kim HJ, Michor F, Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. The Journal of Clinical Investigation. 120: 636-44. PMID 20101094 DOI: 10.1172/Jci40724 |
0.448 |
|
| 2010 |
Foo J, Michor F. Evolution of resistance to anti-cancer therapy during general dosing schedules. Journal of Theoretical Biology. 263: 179-88. PMID 20004211 DOI: 10.1016/J.Jtbi.2009.11.022 |
0.358 |
|
| 2010 |
Haeno H, Michor F. The evolution of tumor metastases during clonal expansion. Journal of Theoretical Biology. 263: 30-44. PMID 19917298 DOI: 10.1016/J.Jtbi.2009.11.005 |
0.443 |
|
| 2009 |
Foo J, Michor F. Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. Plos Computational Biology. 5: e1000557. PMID 19893626 DOI: 10.1371/Journal.Pcbi.1000557 |
0.376 |
|
| 2009 |
Haeno H, Levine RL, Gilliland DG, Michor F. A progenitor cell origin of myeloid malignancies. Proceedings of the National Academy of Sciences of the United States of America. 106: 16616-21. PMID 19805346 DOI: 10.1073/Pnas.0908107106 |
0.443 |
|
| 2009 |
Foo J, Drummond MW, Clarkson B, Holyoake T, Michor F. Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. Plos Computational Biology. 5: e1000503. PMID 19749982 DOI: 10.1371/Journal.Pcbi.1000503 |
0.328 |
|
| 2009 |
Attolini CS, Michor F. Evolutionary theory of cancer. Annals of the New York Academy of Sciences. 1168: 23-51. PMID 19566702 DOI: 10.1111/J.1749-6632.2009.04880.X |
0.373 |
|
| 2008 |
Liso A, Castiglione F, Cappuccio A, Stracci F, Schlenk RF, Amadori S, Thiede C, Schnittger S, Valk PJ, Döhner K, Martelli MF, Schaich M, Krauter J, Ganser A, Martelli MP, ... ... Michor F, et al. A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). Haematologica. 93: 1219-26. PMID 18603563 DOI: 10.3324/Haematol.13209 |
0.34 |
|
| 2008 |
Michor F. Mathematical models of cancer stem cells. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2854-61. PMID 18539964 DOI: 10.1200/Jco.2007.15.2421 |
0.428 |
|
| 2008 |
Olshen A, Quintαs-Cardama A, Kantarjian HM, Gonen M, Michor F, Cortes J. Modelling BCR-ABL1 Dynamics in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) during Frontline Therapy with High-Dose Imatinib, Nilotinib, or Dasatinib. Blood. 112: 3240-3240. DOI: 10.1182/Blood.V112.11.3240.3240 |
0.303 |
|
| 2007 |
Haeno H, Iwasa Y, Michor F. The evolution of two mutations during clonal expansion. Genetics. 177: 2209-21. PMID 18073428 DOI: 10.1534/Genetics.107.078915 |
0.439 |
|
| 2007 |
Michor F. Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia. Trends in Pharmacological Sciences. 28: 197-9. PMID 17412430 DOI: 10.1016/J.Tips.2007.03.003 |
0.334 |
|
| 2007 |
Dingli D, Traulsen A, Michor F, Michor F. (A)symmetric stem cell replication and cancer. Plos Computational Biology. 3: e53. PMID 17367205 DOI: 10.1371/journal.pcbi.0030053 |
0.335 |
|
| 2007 |
Dingli D, Michor F, Antal T, Pacheco JM. The emergence of tumor metastases. Cancer Biology & Therapy. 6: 383-90. PMID 17312385 DOI: 10.4161/Cbt.6.3.3720 |
0.38 |
|
| 2007 |
Michor F. Chronic myeloid leukemia blast crisis arises from progenitors. Stem Cells (Dayton, Ohio). 25: 1114-8. PMID 17218393 DOI: 10.1634/Stemcells.2006-0638 |
0.365 |
|
| 2007 |
Dingli D, Traulsen A, Michor F. Correction: (A)Symmetric Stem Cell Replication and Cancer Plos Computational Biology. 3: e83. DOI: 10.1371/Journal.Pcbi.0030083 |
0.332 |
|
| 2007 |
Michor F. Reply: The long-term response to imatinib treatment of CML [2] British Journal of Cancer. 96: 679-680. DOI: 10.1038/Sj.Bjc.6603604 |
0.314 |
|
| 2006 |
Abbott LH, Michor F. Mathematical models of targeted cancer therapy. British Journal of Cancer. 95: 1136-41. PMID 17031409 DOI: 10.1038/Sj.Bjc.6603310 |
0.381 |
|
| 2006 |
Michor F, Iwasa Y, Nowak MA. The age incidence of chronic myeloid leukemia can be explained by a one-mutation model. Proceedings of the National Academy of Sciences of the United States of America. 103: 14931-4. PMID 17001000 DOI: 10.1073/Pnas.0607006103 |
0.543 |
|
| 2006 |
Dingli D, Michor F. Successful therapy must eradicate cancer stem cells. Stem Cells (Dayton, Ohio). 24: 2603-10. PMID 16931775 DOI: 10.1634/Stemcells.2006-0136 |
0.415 |
|
| 2006 |
Iwasa Y, Nowak MA, Michor F. Evolution of resistance during clonal expansion. Genetics. 172: 2557-66. PMID 16636113 DOI: 10.1534/Genetics.105.049791 |
0.54 |
|
| 2006 |
Michor F, Iwasa Y. Dynamics of metastasis suppressor gene inactivation. Journal of Theoretical Biology. 241: 676-89. PMID 16497335 DOI: 10.1016/J.Jtbi.2006.01.006 |
0.472 |
|
| 2006 |
Michor F, Nowak MA, Iwasa Y. Evolution of resistance to cancer therapy. Current Pharmaceutical Design. 12: 261-71. PMID 16454743 DOI: 10.2174/138161206775201956 |
0.539 |
|
| 2006 |
Nowak MA, Michor F, Iwasa Y. Genetic instability and clonal expansion. Journal of Theoretical Biology. 241: 26-32. PMID 16405914 DOI: 10.1016/J.Jtbi.2005.11.012 |
0.552 |
|
| 2006 |
Brumer Y, Michor F, Shakhnovich EI. Genetic instability and the quasispecies model. Journal of Theoretical Biology. 241: 216-22. PMID 16386760 DOI: 10.1016/J.Jtbi.2005.11.018 |
0.41 |
|
| 2006 |
Michor F, Nowak MA, Iwasa Y. Stochastic dynamics of metastasis formation. Journal of Theoretical Biology. 240: 521-30. PMID 16343545 DOI: 10.1016/J.Jtbi.2005.10.021 |
0.589 |
|
| 2006 |
Hauert C, Michor F, Nowak MA, Doebeli M. Synergy and discounting of cooperation in social dilemmas. Journal of Theoretical Biology. 239: 195-202. PMID 16242728 DOI: 10.1016/J.Jtbi.2005.08.040 |
0.409 |
|
| 2005 |
Michor F, Iwasa Y, Lengauer C, Nowak MA. Dynamics of colorectal cancer. Seminars in Cancer Biology. 15: 484-93. PMID 16055342 DOI: 10.1016/J.Semcancer.2005.06.005 |
0.556 |
|
| 2005 |
Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA. Dynamics of chronic myeloid leukaemia. Nature. 435: 1267-70. PMID 15988530 DOI: 10.1038/Nature03669 |
0.559 |
|
| 2005 |
Michor F. Chromosomal instability and human cancer. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 360: 631-5. PMID 15897185 DOI: 10.1098/Rstb.2004.1617 |
0.403 |
|
| 2005 |
Iwasa Y, Michor F, Komarova NL, Nowak MA. Population genetics of tumor suppressor genes. Journal of Theoretical Biology. 233: 15-23. PMID 15615616 DOI: 10.1016/J.Jtbi.2004.09.001 |
0.569 |
|
| 2005 |
Michor F, Iwasa Y, Vogelstein B, Lengauer C, Nowak MA. Can chromosomal instability initiate tumorigenesis? Seminars in Cancer Biology. 15: 43-9. PMID 15613287 DOI: 10.1016/J.Semcancer.2004.09.007 |
0.547 |
|
| 2005 |
Iwasa Y, Michor F, Nowak MA. Virus evolution within patients increases pathogenicity. Journal of Theoretical Biology. 232: 17-26. PMID 15498589 DOI: 10.1016/J.Jtbi.2004.07.016 |
0.417 |
|
| 2004 |
Jones NA, Wei X, Flower DR, Wong M, Michor F, Saag MS, Hahn BH, Nowak MA, Shaw GM, Borrow P. Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. The Journal of Experimental Medicine. 200: 1243-56. PMID 15545352 DOI: 10.1084/Jem.20040511 |
0.428 |
|
| 2004 |
Nowak MA, Michor F, Komarova NL, Iwasa Y. Evolutionary dynamics of tumor suppressor gene inactivation. Proceedings of the National Academy of Sciences of the United States of America. 101: 10635-8. PMID 15252197 DOI: 10.1073/Pnas.0400747101 |
0.578 |
|
| 2004 |
Iwasa Y, Michor F, Nowak M. Some basic properties of immune selection. Journal of Theoretical Biology. 229: 179-88. PMID 15207473 DOI: 10.1016/J.Jtbi.2004.03.013 |
0.431 |
|
| 2004 |
Iwasa Y, Michor F, Nowak MA. Stochastic tunnels in evolutionary dynamics. Genetics. 166: 1571-9. PMID 15082570 DOI: 10.1534/Genetics.166.3.1571 |
0.527 |
|
| 2004 |
Michor F, Iwasa Y, Nowak MA. Dynamics of cancer progression. Nature Reviews. Cancer. 4: 197-205. PMID 14993901 DOI: 10.1038/Nrc1295 |
0.569 |
|
| 2004 |
Michor F, Iwasa Y, Rajagopalan H, Lengauer C, Nowak MA. Linear model of colon cancer initiation. Cell Cycle (Georgetown, Tex.). 3: 358-62. PMID 14726709 DOI: 10.4161/Cc.3.3.690 |
0.601 |
|
| 2004 |
Iwasa Y, Michor F, Nowak MA. Evolutionary dynamics of invasion and escape. Journal of Theoretical Biology. 226: 205-14. PMID 14643190 DOI: 10.1016/J.Jtbi.2003.08.014 |
0.502 |
|
| 2003 |
Iwasa Y, Michor F, Nowak MA. Evolutionary dynamics of escape from biomedical intervention. Proceedings. Biological Sciences / the Royal Society. 270: 2573-8. PMID 14728779 DOI: 10.1098/Rspb.2003.2539 |
0.5 |
|
| 2003 |
Nowak MA, Michor F, Iwasa Y. The linear process of somatic evolution. Proceedings of the National Academy of Sciences of the United States of America. 100: 14966-9. PMID 14657359 DOI: 10.1073/Pnas.2535419100 |
0.56 |
|
| 2003 |
Michor F, Frank SA, May RM, Iwasa Y, Nowak MA. Somatic selection for and against cancer. Journal of Theoretical Biology. 225: 377-82. PMID 14604590 DOI: 10.1016/S0022-5193(03)00267-4 |
0.681 |
|
| 2003 |
Michor F, Nowak MA, Frank SA, Iwasa Y. Stochastic elimination of cancer cells. Proceedings. Biological Sciences / the Royal Society. 270: 2017-24. PMID 14561289 DOI: 10.1098/Rspb.2003.2483 |
0.534 |
|
| 2003 |
Michor F, Iwasa Y, Komarova NL, Nowak MA. Local regulation of homeostasis favors chromosomal instability. Current Biology : Cb. 13: 581-4. PMID 12676089 DOI: 10.1016/S0960-9822(03)00172-6 |
0.558 |
|
| 2002 |
Michor F, Nowak MA. Evolution: the good, the bad and the lonely. Nature. 419: 677, 679. PMID 12384681 DOI: 10.1038/419677A |
0.401 |
|
| Show low-probability matches. |